Compare

Entera Bio/$ENTX

1D1W1M3M6MYTD1Y5YMAX

About Entera Bio

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.
Ticker
$ENTX
Sector
Health
Primary listing
NASDAQ
Employees
21
Headquarters
Jerusalem, Israel
Website
enterabio.com

Entera Bio Metrics

BasicAdvanced
$561M
-
-$0.41
-
-

What the Analysts think about Entera Bio

Analyst ratings (Buy, Hold, Sell) for Entera Bio stock.
Analyst projections of the future price of Entera Bio stock.

Bulls say / Bears say

The FDA has accepted a single Phase 3 trial of about 750 women, using 12-month hip bone density as the main measure, to support a potential application for EB613. This gives Entera a defined route to a filing, with results expected in the second half of 2028. (Entera Bio Ltd.)
EB613 met its Phase 2 bone-density endpoints, and a small Phase 1 study found that the single-tablet version had a similar drug-exposure profile to injectable Forteo. If confirmed in larger trials, an oral tablet could make anabolic osteoporosis treatment more convenient for patients. (Entera Bio Ltd.)
A $275 million private placement is expected to fund the EB613 programme through a potential FDA application and support operations into 2030. That gives Entera substantial time to pursue its lead programme and advance EB612 with OPKO without an immediate need to raise more capital. (Entera Bio Ltd.)
The encouraging October bone-density findings came from a post-hoc analysis with only six participants contributing to the hip result and nine to the spine result. They are exploratory, and the larger Phase 3 trial is still needed to confirm the effect, with results not expected until the second half of 2028. (Entera Bio Ltd., Entera Bio Ltd.)
The July financing came with substantial dilution: Entera issued about 123 million ordinary shares and pre-funded warrants for a further 11.8 million shares. That greatly expands the share count and can limit gains for existing shareholders even if the cash funds the trial. (SEC)
Entera has no meaningful product revenue and remains loss-making as it funds development. In the second quarter of 2026, R&D spending rose to $3.2 million from $1.5 million a year earlier, while the net loss widened to $7.3 million from $2.7 million. (Entera Bio Ltd.)
Data summarised monthly by Lightyear AI. Last updated on 31 Oct 2026.

Entera Bio Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.